Simultaneous Autophagy and Androgen Receptor Inhibition in a Prostate Cancer Xenograft Model

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Oct 16

PMID 39409882

Authors

Souzan Salemi

Benedikt Kranzbuhler

Valentin Baumgartner

Lara Breitenmoser

Aleksandar Kuzmanov

Fabienne Lehner

Daniel Eberli

Affiliations

Soon will be listed here.

Abstract

Objective: Abi, when used in conjunction with prednisone, is an established treatment for advanced PCa. Our goal was to explore the level of autophagy induced by Abi treatment, both alone and in combination with the autophagy inhibitor Chl, in a castrated mouse xenograft model.

Methods: LNCaP cells were injected into the left and right sides of the back of nude mice that had been previously castrated. Mice were divided into four groups and treated daily with intraperitoneal injections of vehicle (control), Abi (10 mg/kg), Abi (10 mg/kg) combined with Chl (10 mg/kg), or Chl (10 mg/kg), and were monitored for periods of 2 and 3 weeks.

Results: A significant reduction in tumor weight was observed in mice treated with the combination therapy, as opposed to those receiving vehicle control, Abi, or Chl alone. Mice receiving Abi + Chl exhibited reduced expression of ATG5, Beclin 1, and LC3 punctuations, along with an increase in P62, as determined by immunofluorescence and WES analysis. AR expression decreased significantly in all treatment groups compared to the control. PSMA expression was highest in the vehicle and combined treatment groups after 3 weeks, with a significant reduction observed with Chl treatment.

Conclusions: These findings demonstrate that Abi + Chl treatment lowers autophagy levels and suppresses tumors more effectively than Abi alone.

References

Guo S, Miao M, Wu Y, Pan D, Wu Q, Kang Z . DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer. Oncogene. 2024; 43(19):1399-1410. DOI: 10.1038/s41388-024-03005-4. View

Mortezavi A, Salemi S, Kranzbuhler B, Gross O, Sulser T, Simon H . Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancer. World J Urol. 2018; 37(2):351-358. DOI: 10.1007/s00345-018-2385-5. View

Apel A, Herr I, Schwarz H, Rodemann H, Mayer A . Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res. 2008; 68(5):1485-94. DOI: 10.1158/0008-5472.CAN-07-0562. View

Rangwala R, Leone R, Chang Y, Fecher L, Schuchter L, Kramer A . Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014; 10(8):1369-79. PMC: 4203514. DOI: 10.4161/auto.29118. View

Mizushima N, Komatsu M . Autophagy: renovation of cells and tissues. Cell. 2011; 147(4):728-41. DOI: 10.1016/j.cell.2011.10.026. View

Eberli D, Kranzbuhler B, Mortezavi A, Sulser T, Salemi S . Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells. Urol Oncol. 2020; 38(8):683.e19-683.e26. DOI: 10.1016/j.urolonc.2020.04.030. View

Lam J, Leppert J, Vemulapalli S, Shvarts O, Belldegrun A . Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006; 175(1):27-34. DOI: 10.1016/S0022-5347(05)00034-0. View

Bouhajib M, Tayab Z . Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects. Clin Drug Investig. 2019; 39(3):309-317. DOI: 10.1007/s40261-019-00752-1. View

Saleem A, Dvorzhinski D, Santanam U, Mathew R, Bray K, Stein M . Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate. 2012; 72(12):1374-81. PMC: 3840901. DOI: 10.1002/pros.22487. View

10.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B . Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019; 20(5):686-700. DOI: 10.1016/S1470-2045(19)30082-8. View

11.

Mortezavi A, Salemi S, Rupp N, Ruschoff J, Hermanns T, Poyet C . Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. Oncotarget. 2017; 8(19):31765-31774. PMC: 5458246. DOI: 10.18632/oncotarget.15986. View

12.

Eberli D, Kranzbuhler B, Prause L, Baumgartner V, Preda S, Sousa R . Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer. J Cancer Res Clin Oncol. 2022; 148(12):3351-3360. PMC: 9587065. DOI: 10.1007/s00432-022-04059-1. View

13.

Taneja S . Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. J Urol. 2018; 199(1):26-28. DOI: 10.1016/j.juro.2017.10.007. View

14.

Rubinsztein D, Gestwicki J, Murphy L, Klionsky D . Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 2007; 6(4):304-12. DOI: 10.1038/nrd2272. View

15.

Tanida I, Waguri S . Measurement of autophagy in cells and tissues. Methods Mol Biol. 2010; 648:193-214. DOI: 10.1007/978-1-60761-756-3_13. View

16.

Hope T, Truillet C, Ehman E, Afshar-Oromieh A, Aggarwal R, Ryan C . 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2016; 58(1):81-84. PMC: 5209643. DOI: 10.2967/jnumed.116.181800. View

17.

Dong L, Zieren R, Xue W, de Reijke T, Pienta K . Metastatic prostate cancer remains incurable, why?. Asian J Urol. 2019; 6(1):26-41. PMC: 6363601. DOI: 10.1016/j.ajur.2018.11.005. View

18.

Wu Z, Chang P, Yang J, Chu C, Wang L, Chen N . Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer. 2010; 1(1):40-9. PMC: 2930266. DOI: 10.1177/1947601909358324. View

19.

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

20.

Rosenfeld M, Ye X, Supko J, Desideri S, Grossman S, Brem S . A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014; 10(8):1359-68. PMC: 4203513. DOI: 10.4161/auto.28984. View